Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Diamondback Energy Inc (FANG) vs Cassava Sciences Inc (FLNA) Price & Performance

Diamondback Energy IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Diamondback Energy Inc vs Cassava Sciences Inc — how do they compare? Diamondback Energy Inc trades at $200.95 (market cap $56.48B), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: Diamondback Energy Inc is far larger — about 1182.8× Cassava Sciences Inc's market cap, and Diamondback Energy Inc pays a 2.18% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FANGFLNA
Market Cap
$56.48B$47.75M
Sector
EnergyHealth
52-Week High
$213.69$4.64
52-Week Low
$134.53$0.87
Enterprise Value
$68.63B-$34.93M
Dividend Yield
2.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Diamondback Energy Inc

Diamondback Energy (FANG) trades at $200.97, up 1.01% with strong bullish technical signals and positive earnings momentum. The company delivered Q2 2026 EPS of $6.48, beating estimates by 6.6%, while revenue growth accelerated to $14.93B in 2025. Analyst consensus remains overwhelmingly bullish with 90% buy ratings and a $236.63 price target, representing 18% upside potential. Recent news highlights operational excellence and production growth guidance increases.

The outlook remains positive with production growth and debt reduction supporting valuation expansion. Key risks include oil price volatility and execution challenges amid global supply disruptions. Institutional interest remains strong with recent positions from Balefire LLC, though some trimming occurred from Bank of Nova Scotia. The combination of earnings beats, improved guidance, and favorable technicals suggests continued upward momentum.

Cassava Sciences Inc

FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.

The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Diamondback Energy Inc

Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.

Read more on FANG

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA